[144] Argan, Inc SEC Filing

Rhea-AI Filing Summary

On 31 July 2025, a Form 144 filing for Argan, Inc. (AGX) indicates the proposed sale of 1,604 common shares through broker Raymond James. The shares, valued at an aggregate $384,960, were obtained on 30 July 2025 via an equity-grant/option exercise. With 13.64 million shares outstanding, the planned sale equals roughly 0.012 % of the float, implying a modest personal liquidation rather than a sizable insider exit. The filing also shows that Richard Deily—named in the past-sales section—sold 1,565 shares for $238,381 on 30 Apr 2025. No earnings data or corporate updates accompany the notice, and the signer affirms no undisclosed adverse information. Given the limited volume and routine nature of Rule 144 transactions, the event appears largely immaterial to AGX’s fundamentals or near-term valuation.

Positive

• Sale equals only 0.012 % of outstanding shares, posing negligible dilution or liquidity impact.

Negative

• Insider plans to sell 1,604 shares after having sold 1,565 shares in April, a potential—though minor—sentiment headwind.

Insights

Financial Analyst

TL;DR: Small Rule 144 sale (1,604 shares) worth $385k; <0.02% float, likely immaterial to AGX valuation.

The filing depicts a standard insider transaction: option exercise followed by a modest share sale. The dollar value is limited and represents only 0.012 % of shares outstanding, so liquidity and EPS dilution are unaffected. Prior sales of 1,565 shares in April further reduce remaining insider exposure. No operational disclosures accompany the form, and the declarant attests to possessing no undisclosed material information. Consequently, the filing is routine, neutral in tone, and should not meaningfully influence investor sentiment or the stock’s risk profile.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Raymond James & Associates 880 Carillon Parkway St. Petersburg FL 33716	1604	384960	13640813	07/31/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/30/2025	EQUITY GRANT	ISSUER			1604	07/30/2025	OPTION EXERCISE

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Richard Deily 4075 Wilson Boulevard Suite 440 Arlington VA 22203	Common Stock	04/30/2025	1565	238380.80

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many AGX shares are being sold under this Form 144?

1,604 common shares are slated for sale.

What is the aggregate market value of the shares?

The total value is $384,960 as stated in the filing.

Who is the selling shareholder named in recent transactions?

The past-sales section lists Richard Deily.

When is the approximate sale date for these shares?

The filer targets 31 July 2025 for execution.

What proportion of Argan’s total shares does this sale represent?

Roughly 0.012 % of the 13.64 million shares outstanding.

Which broker is handling the sale?

The broker of record is Raymond James & Associates.